Poster session and best abstract award

Thursday 16
November
14:10 - 14:55

Location: H1
Moderators: M. Mischi, Eindhoven (NL)
G. Salomon, Hamburg (DE)

EO1

Feasibility Study for avoiding or postponing biopsy using improved imaging: Negative predictive value of micro-ultrasound for subjects with low PSAD

By: Astobieta Odriozola A. ¹, Sanchez A. ², De La Cruz I. ², Pereira J.G. ², Gamarra M. ², Urdaneta F. ², Mora J. ², Ibarluzea G. ²
¹Urología Clínica Bilbao, Urología Clínica, Bilbao, Spain, ²Urología Clínica Bilbao, Clínica IMQ Zorrotzaurre, Bilbao, Spain

14:14 - 14:16 Discussion

EO2

Diagnostic accuracy of MRI-Transrectal Ultrasound Fusion prostate Biopsy in men with previous prostate biopsies: Preliminary results of the FUPROS16 project

By: Gomez Gomez E.G.G. ¹, Valero Rosa J. ², Carrasco-Valiente J. ², Lopez Ruiz D. ³, Triviño F. ³, Anglada-Curado F.J. ², Blanca A. ⁴, Campos Hernandez J.P. ², Luque R.M. ⁵, Requena Tapia M.J. ²
¹Maimonides Institute of Biomedical Research of Cordoba/Reina Sofia University Hospital, Hormones and Cancer/urology, Cordoba, Spain, ²Maimonides Institute of Biomedical Research of Cordoba/Reina Sofia University Hospital, Dept. of Urology, Cordoba, Spain, ³Maimonides Institute of Biomedical Research of Cordoba/Reina Sofia University Hospital, Dept. of Radiology, Cordoba, Spain, ⁴Maimonides Institute of Biomedical Research of Cordoba, Dept. of Urology, Cordoba, Spain, ⁵Maimonides Institute of Biomedical Research of Cordoba/University of Cordoba, Dept. of Cellular Biology, Cordoba, Spain

14:20 - 14:22 Discussion

EO6

Ultrasonographic study in patients affected by Peyronie's disease with absence of palpable plaques or deformity of the penis

By: Dell'Atti L., Galosi A.B.
University Hospital "ospedali Riuniti", Dept. of Urology, Ancona, Italy

14:26 - 14:28 Discussion

EO4

MR spectroscopy provides distinction between malignant clear cell renal cancers and indolent subtypes
By: Del Vecchio S.¹, Ellis R.¹, Urquhart A.², Galloway G.², Gobe G.¹, Mountford C.², Wood S.³
¹Translational Research Institute, Dept. of Kidney Disease Research, Woolloongabba, Australia, ²Translational Research Institute, Diagnostic Imaging Flagship, Brisbane, Australia, ³Princess Alexandra Hospital, Dept. of Urology, Brisbane, Australia

14:32 - 14:34
Discussion

EO5

11C-choline PET-guided salvage intensity modulated radiotherapy with simultaneous integrated boost for isolated pelvic and para-aortic prostate cancer nodal recurrences: Minimal adverse effects

By: Jethwa K.¹, Davis B.², Hellekson C.², Evans J.², Whitaker T.², Wilhite T.², Park S.², Choo C.², Stish B.², Olivier K.², Lowe V.³, Johnson G.³, Mynderse L.⁴, Welch T.³, Quevedo F.⁵, Karnes R.⁴, Kwon E.⁴
¹Mayo Clinic, Dept. Of Radiation Oncology, Rochester, United States of America, ²Mayo Clinic, Dept. of Radiation Oncology, Rochester, United States of America, ³Mayo Clinic, Dept. of Radiology, Rochester, United States of America, ⁴Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁵Mayo Clinic, Dept. of Medical Oncology, Rochester, United States of America

14:38 - 14:40
Discussion

EO3

Ga-68 PSMA PETCT response to androgen deprivation therapy in patients with prostate cancer

By: Murthy V.¹, Gupta P.¹, Agrawal A.², Maitre M.¹, Krishnatry R.¹, Rangarajan V.²
¹Tata Memorial Hospital, Dept. of Radiation Oncology, Mumbai, India, ²Tata Memorial Hospital, Dept. of Bioimaging, Mumbai, India

14:44 - 14:46
Discussion

14:46 - 14:55
Award best abstract
G. Salomon, Hamburg (DE)